Mercer Capital Advisers Inc. maintained its stake in Zoetis Inc. (NYSE:ZTS) during the second quarter, Holdings Channel reports. The firm owned 3,475 shares of the company’s stock at the end of the second quarter. Mercer Capital Advisers Inc.’s holdings in Zoetis were worth $217,000 as of its most recent filing with the SEC.
A number of other large investors have also bought and sold shares of the company. DAVENPORT & Co LLC raised its stake in Zoetis by 24.7% in the first quarter. DAVENPORT & Co LLC now owns 359,906 shares of the company’s stock valued at $19,231,000 after buying an additional 71,360 shares during the last quarter. Ameriprise Financial Inc. raised its stake in Zoetis by 21.1% in the first quarter. Ameriprise Financial Inc. now owns 1,614,416 shares of the company’s stock valued at $86,167,000 after buying an additional 281,139 shares during the last quarter. Gladstone Capital Management LLP acquired a new stake in Zoetis during the second quarter valued at approximately $3,134,000. Harbour Capital Advisors LLC raised its stake in Zoetis by 19.8% in the first quarter. Harbour Capital Advisors LLC now owns 20,005 shares of the company’s stock valued at $1,068,000 after buying an additional 3,300 shares during the last quarter. Finally, AXA raised its stake in Zoetis by 0.8% in the first quarter. AXA now owns 242,831 shares of the company’s stock valued at $12,960,000 after buying an additional 1,900 shares during the last quarter. 95.22% of the stock is currently owned by institutional investors and hedge funds.
Zoetis Inc. (NYSE:ZTS) opened at 62.12 on Friday. The stock’s 50 day moving average is $62.59 and its 200 day moving average is $57.66. The stock has a market capitalization of $30.49 billion, a PE ratio of 36.12 and a beta of 1.02. Zoetis Inc. has a 12-month low of $46.86 and a 12-month high of $63.85.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 4th. The company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.05. The company had revenue of $1.23 billion during the quarter, compared to analysts’ expectations of $1.20 billion. Zoetis had a net margin of 17.25% and a return on equity of 65.35%. Zoetis’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period last year, the business earned $0.48 EPS. Equities analysts anticipate that Zoetis Inc. will post $2.33 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Thursday, June 15th will be paid a $0.105 dividend. This represents a $0.42 dividend on an annualized basis and a yield of 0.68%. The ex-dividend date of this dividend is Tuesday, June 13th. Zoetis’s dividend payout ratio (DPR) is presently 24.42%.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/05/zoetis-inc-nysezts-position-held-by-mercer-capital-advisers-inc.html.
ZTS has been the topic of several research reports. Deutsche Bank AG reissued a “buy” rating and set a $65.00 price objective (up previously from $62.00) on shares of Zoetis in a research note on Monday, July 17th. BMO Capital Markets reissued a “buy” rating and set a $60.00 price objective on shares of Zoetis in a research note on Thursday, May 4th. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $67.00 price objective on the stock in a research note on Wednesday, May 10th. Argus reissued a “buy” rating and set a $69.00 price objective (up previously from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. Finally, Hilliard Lyons initiated coverage on shares of Zoetis in a research note on Tuesday, June 20th. They set a “buy” rating and a $77.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $64.94.
In related news, insider Catherine A. Knupp sold 5,785 shares of Zoetis stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $60.16, for a total value of $348,025.60. Following the completion of the sale, the insider now directly owns 24,415 shares in the company, valued at approximately $1,468,806.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.31% of the stock is owned by company insiders.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
